Hypofractionated Radiation Therapy for Basal and Squamous Cell Skin Cancer: A Meta-analysis

Overview

Journal Radiother Oncol

Specialties Oncology
Radiology

Date 2017 Aug 28

PMID 28843727

Citations 25

Authors

Nicholas G Zaorsky

Charles T Lee

Eddie Zhang

Scott W Keith

Thomas J Galloway

Affiliations

Soon will be listed here.

Abstract

Purpose: To characterize the cosmetic outcomes and local recurrence (LR) rates of various hypofractionated radiation therapy (RT) regimens for skin basal and squamous cell cancers (BCCs/SCCs).

Methods: A PICOS/PRISMA/MOOSE selection protocol was performed to identify 344 articles published between 1985-2016 evaluating patients with T1-2 N0 SCCs/BCCs treated with definitive RT. Biologically equivalent doses with α/β=3 (BEDs) were calculated. The primary endpoint was post-treatment cosmesis. Mixed effects regression models were used to estimate weighted linear relationships between BED and cosmetic outcomes.

Results: A total of 21 studies were identified detailing the treatment of 9729 skin BCC/SCC patients, across seven countries, with external beam RT (n=9255) or brachytherapy (n=474). Median follow-up was 36months (range: 12-77). Median dose was 45Gy/11 fractions (interquartile range: 37.5Gy/6-55Gy/18) at 4Gy/fraction (interquartile range: 2.5-6Gy); most hypofractionated 18.75Gy/1. There was a trend to decreased "good" cosmesis with higher total dose: -3.4% "good" cosmesis/10Gy BED, p=0.01. Similarly, there was a trend to increased "fair" cosmesis with higher dose: +3.8% "fair" cosmesis/10Gy BEDp=0.006. At a BED of 100Gy, the expected rate of "good" cosmesis is 79% (95% confidence interval: 70%, 88%). Hypofractionated schedules produced similar cosmesis to conventionally fractionated schedules, at the same BED. Fewer than 8% of patients experienced "poor" cosmesis, independent of dose or fractionation regimen.

Conclusion: Hypofractionated RT has favorable cosmesis for patients with skin BCCs/SCCs. We recommend clinicians consider these commonly-used regimens, which all have BED of ∼100Gy: 50Gy/15 fractions, 36.75Gy/7 fractions, or 35Gy/5 fractions, as they result in "good" cosmesis in 80% of patients.

Citing Articles

Palliative Radiotherapy to Preserve Eyesight in a Recurrent, Difficult-to-Treat Basal Cell Carcinoma.

Copilau A, Balaceanu-Gurau B, Anghel A, Tudose I, Mihai M Cureus. 2025; 17(1):e77743.

PMID: 39981494 PMC: 11839891. DOI: 10.7759/cureus.77743.

Radiobiology and modelling in Brachytherapy: A review inspired by the ESTRO Brachytherapy pre-meeting course.

Stewart A, Chargari C, Chyrek A, Eckert F, Guinot J, Hellebust T Clin Transl Radiat Oncol. 2024; 50:100885.

PMID: 39670056 PMC: 11636333. DOI: 10.1016/j.ctro.2024.100885.

Hypofractionated versus standard fractionation radiotherapy for merkel cell carcinoma.

Gonzalez L, Rubens M, Yarlagadda S, Rabinowits G, Kalman N Radiat Oncol. 2024; 19(1):142.

PMID: 39394124 PMC: 11468079. DOI: 10.1186/s13014-024-02516-4.

Cutaneous Squamous Cell Carcinoma in Patients with Solid-Organ-Transplant-Associated Immunosuppression.

Khaddour K, Murakami N, Ruiz E, Silk A Cancers (Basel). 2024; 16(17).

PMID: 39272941 PMC: 11394667. DOI: 10.3390/cancers16173083.

Cutaneous Oncology: Strategies for Melanoma Prevention, Diagnosis, and Therapy.

Saeed W, Shahbaz E, Maqsood Q, Ali S, Mahnoor M Cancer Control. 2024; 31:10732748241274978.

PMID: 39133519 PMC: 11320697. DOI: 10.1177/10732748241274978.

References

Hawkey N, Zaorsky N, Galloway T . The role of radiation therapy in the management of sialorrhea: A systematic review. Laryngoscope. 2015; 126(1):80-5. DOI: 10.1002/lary.25444. View

Karimkhani C, Dellavalle R, Coffeng L, Flohr C, Hay R, Langan S . Global Skin Disease Morbidity and Mortality: An Update From the Global Burden of Disease Study 2013. JAMA Dermatol. 2017; 153(5):406-412. PMC: 5817488. DOI: 10.1001/jamadermatol.2016.5538. View

Avkshtol V, Dong Y, Hayes S, Hallman M, Price R, Sobczak M . A comparison of robotic arm versus gantry linear accelerator stereotactic body radiation therapy for prostate cancer. Res Rep Urol. 2016; 8:145-58. PMC: 4993397. DOI: 10.2147/RRU.S58262. View

Ashby M, Smith J, Ainslie J, McEwan L . Treatment of nonmelanoma skin cancer at a large Australian center. Cancer. 1989; 63(9):1863-71. DOI: 10.1002/1097-0142(19900501)63:9<1863::aid-cncr2820630934>3.0.co;2-4. View

Goyal U, Kim Y, Arif Tiwari H, Witte R, Stea B . A pilot study of ultrasound-guided electronic brachytherapy for skin cancer. J Contemp Brachytherapy. 2015; 7(5):374-80. PMC: 4663218. DOI: 10.5114/jcb.2015.55538. View

Zaorsky N, Palmer J, Hurwitz M, Keith S, Dicker A, Den R . What is the ideal radiotherapy dose to treat prostate cancer? A meta-analysis of biologically equivalent dose escalation. Radiother Oncol. 2015; 115(3):295-300. DOI: 10.1016/j.radonc.2015.05.011. View

Whelan T, Pignol J, Levine M, Julian J, MacKenzie R, Parpia S . Long-term results of hypofractionated radiation therapy for breast cancer. N Engl J Med. 2010; 362(6):513-20. DOI: 10.1056/NEJMoa0906260. View

Hall V, Leppard B, McGill J, Kesseler M, White J, Goodwin P . Treatment of basal-cell carcinoma: comparison of radiotherapy and cryotherapy. Clin Radiol. 1986; 37(1):33-4. DOI: 10.1016/s0009-9260(86)80161-1. View

Johnson M, Zaorsky N, Martin J, Ruth K, Greenberg R, Uzzo R . Patient reported outcomes among treatment modalities for prostate cancer. Can J Urol. 2016; 23(6):8535-8545. View

10.

Tormo A, Celada F, Rodriguez S, Botella R, Ballesta A, Kasper M . Non-melanoma skin cancer treated with HDR Valencia applicator: clinical outcomes. J Contemp Brachytherapy. 2014; 6(2):167-72. PMC: 4105643. DOI: 10.5114/jcb.2014.43247. View

11.

Koshy M, Malik R, Weichselbaum R, Sher D . Increasing radiation therapy dose is associated with improved survival in patients undergoing stereotactic body radiation therapy for stage I non-small-cell lung cancer. Int J Radiat Oncol Biol Phys. 2015; 91(2):344-50. DOI: 10.1016/j.ijrobp.2014.10.002. View

12.

Caccialanza M, Piccinno R, Kolesnikova L, Gnecchi L . Radiotherapy of skin carcinomas of the pinna: a study of 115 lesions in 108 patients. Int J Dermatol. 2005; 44(6):513-7. DOI: 10.1111/j.1365-4632.2005.02103.x. View

13.

Moher D, Liberati A, Tetzlaff J, Altman D . Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann Intern Med. 2009; 151(4):264-9, W64. DOI: 10.7326/0003-4819-151-4-200908180-00135. View

14.

Zaorsky N, Churilla T, Egleston B, Fisher S, Ridge J, Horwitz E . Causes of death among cancer patients. Ann Oncol. 2016; 28(2):400-407. PMC: 5834100. DOI: 10.1093/annonc/mdw604. View

15.

Churchill-Davidson I, Johnson E . Rodent ulcers: an analysis of 711 lesions treated by radiotherapy. Br Med J. 1954; 1(4877):1465-8. PMC: 2085373. DOI: 10.1136/bmj.1.4877.1465. View

16.

Bonerandi J, Beauvillain C, Caquant L, Chassagne J, Chaussade V, Clavere P . Guidelines for the diagnosis and treatment of cutaneous squamous cell carcinoma and precursor lesions. J Eur Acad Dermatol Venereol. 2011; 25 Suppl 5:1-51. DOI: 10.1111/j.1468-3083.2011.04296.x. View

17.

Meng M, Wang H, Zaorsky N, Zhao X, Wu Z, Jiang B . Clinical evaluation of stereotactic radiation therapy for recurrent or second primary mediastinal lymph node metastases originating from non-small cell lung cancer. Oncotarget. 2015; 6(17):15690-703. PMC: 4558180. DOI: 10.18632/oncotarget.3704. View

18.

Palmer J, Zaorsky N, Witek M, Lu B . Molecular markers to predict clinical outcome and radiation induced toxicity in lung cancer. J Thorac Dis. 2014; 6(4):387-98. PMC: 3968560. DOI: 10.3978/j.issn.2072-1439.2013.12.04. View

19.

Pampena R, Palmieri T, Kyrgidis A, Ramundo D, Iotti C, Lallas A . Orthovoltage radiotherapy for nonmelanoma skin cancer (NMSC): Comparison between 2 different schedules. J Am Acad Dermatol. 2015; 74(2):341-7. DOI: 10.1016/j.jaad.2015.09.031. View

20.

Zaorsky N, Shaikh T, Handorf E, Eastwick G, Hesney A, Scher E . What Are Medical Students in the United States Learning About Radiation Oncology? Results of a Multi-Institutional Survey. Int J Radiat Oncol Biol Phys. 2015; 94(2):235-42. PMC: 7548032. DOI: 10.1016/j.ijrobp.2015.10.008. View